Value of inflammatory，pyroptosis，and ferroptosis biomarkers in the treatment and prognosis of bladder cancer

Abstract:

According to Global Cancer Statistics 2020，bladder cancer is the tenth most commonly diagnosed cancer worldwide，which is the sixth most common cancer and the ninth leading cause of cancer-related death in men. Although the exact pathogenesis of bladder cancer is unclear，certain factors have been demonstrated to be associated with an increased risk of bladder cancer，such as smoking，chemical exposure，age，sex，genetic factors，and environmental factors. Bladder cancer can cause pain，urinary tract infection，urinary incontinence，and death，which can impose a huge health and economic burden on patients. To better prevent and treat bladder cancer，the detection of biomarkers can help monitor or predict the development，progression，or treatment of bladder cancer. In recent years，studies have shown that the development of bladder cancer is closely related to various mechanisms including inflammation，pyroptosis，and ferroptosis，and these molecular mechanisms-related biomarkers have been increasingly applied in the research of bladder cancer. This review focuses on the value of these novel biomarkers in the diagnosis，treatment，and prognosis of bladder cancer，which can be potential targets at different treatment stages of bladder cancer for controlling the disease，prolonging disease-free interval，and inhibiting tumor recurrence and metastasis.